| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Approves Triamcinolone Acetone Formulation for Ocular Use IRVINE, Calif. -- June 17, 2008 -- The US Food and Drug Administration (FDA) has approved triamcinolone acetonide injectable suspension (Trivaris) 80 mg/mL, a synthetic glucocorticoid corticosteroid with anti-inflammatory action. Delivered via intravitreal injection, the ophthalmic indications for triamcinolone acetonide include sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. These are inflammatory conditions that can result in vision loss. Prolonged use of corticosteroids may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections. SOURCE: Allergen Inc.
|